Featured Webinar

How to Reduce Isolation Days

Duration: 58 minutes | Available On Demand

Read more

Summary

In March, the Center for Disease Control and Prevention (CDC) issued a call-to-action to prevent Staphylococcus aureus infections. For several years methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection rates decreased consistently, but the decline slowed from 2013. Methicillin-sensitive Staphylococcus aureus (MSSA) rates have increased since 2012. This presentation discusses the reasons why improvement has stalled. It explores new protocols that allow facilities to directly address MSSA and to resume making progress in MRSA bloodstream infections reduction. These protocols can reduce screening and isolation 50% which has positive effects on patient care and satisfaction, staff “isolation fatigue” and facility operations.

Learning Objectives

  1. Describe the role of the nares in MRSA/MSSA infections.
  2. Describe the risks that MRSA/MSSA nasal carriage represent.
  3. Identify three limitations of current MRSA risk mitigation programs.
  4. Explore the benefits of universal decolonization compared to screen and isolate and targeted decolonization.

Please note this webinar replay is no longer eligible for CE credits.

About the Presenter

Gwen Borlaug, MPH, CIC, FAPIC, worked at the Wisconsin Division of Public Health (DPH) as the Director of the Healthcare-Associated Infection Prevention Program and infection prevention epidemiologist.

As the subject matter expert for MRSA, she revised the DPH guidelines for managing patients with MRSA in healthcare settings, presented numerous educational offerings to local public health officials and healthcare personnel across the state, and served on the Metastar (Wisconsin quality improvement organization) MRSA advisory committee. She launched a statewide public health initiative to reduce surgical site infections, using a surgical care champion to provide peer-to-peer learnings to surgeons and surgical teams in Wisconsin hospitals. She has been an infection preventionist for 22 years and obtained her certification in infection control in 2002. She received an APIC Heroes of Infection Prevention Award and a Chapter Leadership award in 2010 and became an APIC Fellow in 2017.

THE PRESENTER
Gwen Borlaug
MPH, CIC, FAPIC

Webinar

Guidelines for Staphylococcal Decolonization

Recommendations from CDC, SHEA and HRET

Duration: 31 minutes | Available On Demand

Read more

Summary

Increasingly, society and organization guidelines recommend including decolonization protocols to help lower the risk of hospital onset Staphylococcus aureus infections. Nasal and body staphylococcal decolonization include surgical and ICU patients, and among those with certain indwelling devices.

This short presentation shares the recommendations from CDC, SHEA and HRET and considerations in selecting a MRSA risk mitigation program.  Reference guidelines will be available for download.

Learning Objectives

  1. Describe the most recent recommendations guiding staphylococcal nasal decolonization practices.
  2. Describe the three types of decolonization agents available for implementing the recommended practices.
  3. Identify considerations for selecting a risk mitigation program for MRSA colonization.

About the Presenter

Gwen Borlaug, MPH, CIC, FAPIC, is an independent infection prevention consultant, with special interest in offering HAI surveillance data validation services, evaluating hospital infection prevention programs, providing SSI prevention consultation, and reducing multidrug-resistant organisms. She formerly worked at the Wisconsin Division of Public Health (DPH) as the Director of the Healthcare-Associated Infection Prevention Program and infection prevention epidemiologist.


Health Professionals:
Request a comprehensive analysis of your MRSA & MSSA colonization risk mitigation protocols today.

© 2004-2020 Global Life Technologies Corp. All rights reserved. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease. | Patent Nos.
Click to access the login or register cheese